Last reviewed · How we verify
Yellow Fever
Yellow Fever is a Live attenuated vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently FDA-approved for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas. Also known as: YF VAX®.
The yellow fever vaccine stimulates the immune system to produce antibodies and cellular immunity against the yellow fever virus through a live attenuated viral strain.
Yellow Fever is a viral disease of typically short duration, characterized by symptoms such as fever, chills, loss of appetite, nausea, muscle pains, and headaches. If left untreated, the disease can progress to liver damage, causing yellow skin, in about 15% of people.
At a glance
| Generic name | Yellow Fever |
|---|---|
| Also known as | YF VAX® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains a weakened (attenuated) form of the yellow fever virus that replicates in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly neutralize the wild-type yellow fever virus upon natural exposure, providing long-term protective immunity.
Approved indications
- Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas
Common side effects
- Headache
- Myalgia
- Fever
- Injection site reaction (pain, erythema, swelling)
- Fatigue
Key clinical trials
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (PHASE1)
- Phase 3 Single Arm, Open Study on vYF in Adults (PHASE3)
- Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults (PHASE3)
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- VAC-SIP-YF (Vaccination- Safety & Immunogenicity During Pregnancy- Yellow Fever) (NA)
- Antibiotics and Vaccine Immune Responses Study (PHASE4)
- The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yellow Fever CI brief — competitive landscape report
- Yellow Fever updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Yellow Fever
What is Yellow Fever?
How does Yellow Fever work?
What is Yellow Fever used for?
Who makes Yellow Fever?
Is Yellow Fever also known as anything else?
What drug class is Yellow Fever in?
What development phase is Yellow Fever in?
What are the side effects of Yellow Fever?
Related
- Drug class: All Live attenuated vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas
- Also known as: YF VAX®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing